

Analysis of Adverse Event Summary  
(Safety Analysis Population)

	Placebo		Xanomeline Low Dose		Xanomeline High Dose	
	n	(%)	n	(%)	n	(%)
Participants in population	86		84		84	
With one or more adverse events	69	( 80.2)	77	( 91.7)	79	( 94.0)
With drug-related adverse events	44	( 51.2)	73	( 86.9)	70	( 83.3)
With serious adverse events	0	( 0.0)	1	( 1.2)	2	( 2.4)
With serious drug-related adverse events	0	( 0.0)	1	( 1.2)	1	( 1.2)
Who died	2	( 2.3)	1	( 1.2)	0	( 0.0)

Every subject is counted a single time for each applicable row and column.